Key findings towards optimising adalimumab treatment: the concentration–effect curve-Reference-Cited by-同舟云学术

Key findings towards optimising adalimumab treatment: the concentration–effect curve

Published:2013-12-10 Issue:3 Volume:74 Page:513-518
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Pouw Mieke F,Krieckaert Charlotte L,Nurmohamed Michael T,van der Kleij Desiree,Aarden Lucien,Rispens Theo,Wolbink Gertjan

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference29 articles.

1. 2012 EvaluatePharma Ltd., World Preview. 2018. http://www.evaluategroup.com/Public/EvaluatePharma-World-Preview-2018-Embracing-the-Patent-Cliff.aspx (accessed 23 Mar 2013).

2. Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7;Kempeni;Ann Rheum Dis,1999

3. Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody;Kempeni;Ann Rheum Dis,2000

4. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis;Den Broeder;J Rheumatol,2002

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ADALIMUMAB DRUG MONITORING AND TREATMENT ADJUSTMENT TO DRUG ANTIBODIES IN NON-INFECTIOUS UVEITIS;American Journal of Ophthalmology;2024-09

2. What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022;Frontiers in Pharmacology;2024-07-08

3. Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis;Pharmaceutics;2024-05-23

4. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2);Zeitschrift für Gastroenterologie;2024-05

5. Adalimumab Dose Reduction and Withdrawal in Stable Non-Infectious Pediatric Uveitis: An Open-Label, Prospective, Pilot Study;Ocular Immunology and Inflammation;2024-04-23